BBLG Bone Biologics Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1419554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY28.0%
TTM EPS YoY57.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-47.5%
ROA-44.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $1.06M | $2.13M | $6.91M | $1.58M | $82,044 |
| SG&A expense | $2.17M | $2.09M | $2.52M | $2.09M | $1.02M |
| Operating income | -$3.23M | -$4.22M | -$9.43M | -$3.67M | -$1.10M |
| Pretax income | — | — | — | — | -$1.61M |
| Income tax | — | — | — | — | $1,600 |
| Net income | -$3.11M | -$4.11M | -$8.95M | -$1.48M | -$1.61M |
| EPS (basic) | -2.65 | -28.96 | -34.01 | -31.15 | -0.35 |
| EPS (diluted) | -2.65 | -28.96 | -34.01 | -31.15 | -0.35 |
| Weighted avg. shares (diluted) | 1.17M | 252,960 | 263,137 | 47,658 | 4.54M |
| Banking | |||||
| Net interest income | — | — | $1,868 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $5.33M | $3.33M | $3.03M | $7.54M | $6.68M |
| Current assets | $5.80M | $3.86M | $3.74M | $8.50M | — |
| Total assets | $5.80M | $3.86M | $3.74M | $8.50M | $6.68M |
| Current liabilities | $418,587 | $377,712 | $831,402 | $2.55M | $99,909 |
| Total liabilities | $418,587 | $377,712 | $831,402 | $2.55M | $99,909 |
| Shareholders' equity | $5.38M | $3.48M | $2.91M | $5.95M | $6.58M |
| Shares outstanding | 1.80M | 492,417 | 534,238 | 63,820 | 10.35M |
| Cash flow statement | |||||
| Operating cash flow | -$2.69M | -$4.12M | -$9.56M | -$3.57M | -$1.23M |
| Financing cash flow | $4.70M | $4.42M | $5.04M | $4.43M | $7.90M |
| Stock-based compensation | $256,358 | $188,819 | $152,599 | $266,633 | $207,035 |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.